712 IMPORT-201 (IMP-MEL): a phase 1 first-in-human dose finding/randomized phase 2 study of a novel iNKT agonist (PORT-2) and pembrolizumab for advanced melanoma and non-small cell lung cancer (NSCLC)
| Autor: | David Thompson, Mark R Middleton, David J Pinato, Ian Walters, Robert Krämer, Uzi Gileadi, Nicholas Coupe, Justin Fairchild, Russell Poe, Carri Browne, Steven Innaimo, Carmela De Santo |
|---|---|
| Jazyk: | angličtina |
| Rok vydání: | 2023 |
| Předmět: | |
| Zdroj: | Journal for ImmunoTherapy of Cancer, Vol 11, Iss Suppl 1 (2023) |
| Druh dokumentu: | article |
| ISSN: | 2051-1426 |
| DOI: | 10.1136/jitc-2023-SITC2023.0712 |
| Databáze: | Directory of Open Access Journals |
| Externí odkaz: |
|